Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk (NVO), has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.
Financial terms of the projects weren't disclosed.
The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.
Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.
The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。